Dual Therapy With Dolutegravir + 3TC Keep Viral Load Undetectable: 48-Week Results From PADDLE Study
August 6, 2016
Updated results from the PADDLE study were a highlight of AIDS 2016 and were presented as an oral late-breaker on the last day.1
This was a small (n=20) single-arm open label study in treatment-naive participants that was notable for reporting at the EACS 2015 conference that rapid viral suppression to <50 copies by week 8 that was maintained to 24 weeks. Although median baseline viral load was low [24,128 copies/mL (IQR: 11,686-36,794), four people were >100,000 copies/mL.2
The results at week 48 were similar, with suppression maintained to <50 copies/mL throughout in 18/20 participants.
Low level detectable viral load was reported at week 36 in one participant who resuppressed without a change in treatment (even though the study protocol recommended changing).
One participant committed suicide linked to "severe stress and emotional trauma" that was not judged related to the study medications.
These results are encouraging for the likelihood of this being a durable option, however small the dataset.
This article was provided by HIV i-Base. It is a part of the publication HIV Treatment Bulletin. Visit HIV i-Base's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.